We are live on ! Find out more
CRSP icon

CRISPR Therapeutics
CRSP

433 hedge funds and large institutions have $3.52B invested in CRISPR Therapeutics in 2025 Q2 according to their latest regulatory filings, with 101 funds opening new positions, 127 increasing their positions, 101 reducing their positions, and 60 closing their positions.

New
Increased
Maintained
Reduced
Closed

68% more first-time investments, than exits

New positions opened: 101 | Existing positions closed: 60

60% more capital invested

Capital invested by funds: $2.2B → $3.52B (+$1.32B)

31% more call options, than puts

Call options by funds: $244M | Put options by funds: $186M

26% more repeat investments, than reductions

Existing positions increased: 127 | Existing positions reduced: 101

9% more funds holding

Funds holding: 396 → 433 (+37)

8.4% more ownership

Funds ownership: 75.39% → 83.79% (+8.4%)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

Holders
433
Holders Change
+37
Holders Change %
+9.34%
% of All Funds
5.7%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
101
Increased
127
Reduced
101
Closed
60
Calls
$244M
Puts
$186M
Net Calls
+$58.2M
Net Calls Change
+$37.5M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$134M
2
OAG
Orbis Allan Gray
Bermuda
+$46.5M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$39.7M
4
State Street
State Street
Massachusetts
+$33.3M
5
UBS Group
UBS Group
Switzerland
+$29.9M

Top Sellers

Rank Fund Capital Flow
1
UBS AM
UBS AM
Illinois
-$38.2M
2
Morgan Stanley
Morgan Stanley
New York
-$30.5M
3
BBA
Baker Bros. Advisors
New York
-$22.3M
4
Millennium Management
Millennium Management
New York
-$19.9M
5
Capital International Investors
Capital International Investors
California
-$18.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank Julius Baer & Co
251
Bank Julius Baer & Co
Switzerland
$225K -$32.4K -838 -15%
IWA
252
IVC Wealth Advisors
Pennsylvania
$225K +$179K +4,616 New
IFG
253
Independent Financial Group
California
$221K +$176K +4,536 New
NSAM
254
North Star Asset Management
Wisconsin
$219K +$174K +4,505 New
ACA
255
Aptus Capital Advisors
Alabama
$212K +$169K +4,368 New
HA
256
HC Advisors
Georgia
$205K +$163K +4,218 New
AA
257
Ancora Advisors
Ohio
$203K +$13.8K +356 +9%
WA
258
Whipplewood Advisors
Colorado
$201K +$160K +4,132 +82,640%
EP
259
Elkhorn Partners
Nebraska
$195K -$7.74K -200 -5%
GFM
260
GF Fund Management
China
$165K +$47K +1,215 +56%
Mirae Asset Global Investments
261
Mirae Asset Global Investments
South Korea
$162K +$20.1K +519 +18%
MCM
262
MAI Capital Management
Ohio
$156K +$5.57K +144 +5%
CIBC Private Wealth Group
263
CIBC Private Wealth Group
Georgia
$145K +$37.9K +979 +49%
HIA
264
Harbor Investment Advisory
Maryland
$143K -$31.2K -805 -21%
AB
265
Amalgamated Bank
New York
$138K +$109K +2,827 New
SAM
266
Sectoral Asset Management
Quebec, Canada
$124K – – –
FP
267
Financial Perspectives
Minnesota
$118K +$503 +13 +0.5%
Carson Wealth (CWM LLC)
268
Carson Wealth (CWM LLC)
Nebraska
$114K -$56.6K -1,462 -38%
HPC
269
HM Payson & Co
Maine
$113K – – –
SCM
270
Sterling Capital Management
North Carolina
$110K +$87.5K +2,260 New
KBC Group
271
KBC Group
Belgium
$108K -$59.1K -1,526 -41%
SWM
272
Spire Wealth Management
Virginia
$108K +$21.2K +548 +33%
Nisa Investment Advisors
273
Nisa Investment Advisors
Missouri
$108K +$85.6K +2,212 New
RA
274
Rational Advisors
New York
$104K +$82.5K +2,131 New
FDCDDQ
275
Federation des caisses Desjardins du Quebec
Quebec, Canada
$101K +$9.68K +250 +14%
9 10
11
12 13

CRSP Hedge Fund Activity: Q2 2025 in Review

433 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q2 2025, worth a combined $3.52B — up 60% from $2.2B a quarter earlier.

Buyers outnumbered sellers: 101 funds opened new CRSP positions and 60 closed out — a net gain of 41 holders — while 127 added to existing stakes and 101 trimmed.

The largest buyer was BlackRock, adding an estimated $134M. The largest seller was UBS AM, cutting an estimated $38.2M.

  • 433 institutional investors held CRISPR Therapeutics (CRSP) as of Q2 2025, up from 396 in Q1 2025.
  • Funds reported $3.52B of CRISPR Therapeutics stock for Q2 2025, up 60% quarter-over-quarter.
  • 101 funds opened new CRISPR Therapeutics positions in Q2 2025 and 60 closed out, a net change of +41 holders.
  • The largest CRISPR Therapeutics buyer in Q2 2025 was BlackRock, an estimated $134M added.
  • The largest CRISPR Therapeutics seller in Q2 2025 was UBS AM, an estimated $38.2M sold.

Based on aggregated 13F filings for Q2 2025.